Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

NCT05951959 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05951959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05951959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 13, 2023
Completion date
October 31, 2028
Enrollment
108 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma (mcl)